Azacitidine and decitabine belong to a class of antineoplastic agents known as DNA methyltransferase inhibitors (DMTIs). Each is paired with cedazuridine, a cytidine deaminase inhibitor, to help the ...

The abstract can be found on the ASH Annual Meeting website, https://submit.hematology.org/program/presentation/674309 ...

The IDEXX Cancer Dx is a new blood-based screening/diagnostic panel aimed at detecting canine lymphoma from serum or whole ...

The standard measure of lesion count may matter less than the underlying biology driving treatment response in ...

For decades, lung cancer has been associated with stigma, anxiety, and loss. Advances in screening, therapeutics, and ...

The "Fair-Market Value Compensation Rates for Oncology KOLs - Switzerland" report has been added to ResearchAndMarkets.com's offering. KOL FMV Rates Oncology Switzerland presents fair-market value ...

Cancer is increasingly managed as a chronic illness, requiring comprehensive support for patients beyond treatment. Multidisciplinary approaches are essential to address the complex needs of cancer ...

NEW HAVEN, Conn. (WTNH) — In today’s health headlines, Yale Cancer Center researchers are using artificial intelligence in melanoma research and also a new personalized medicine tool to guide breast ...

Citius Oncology is dedicated to advancing cancer treatment with new therapies for unmet needs. Its primary asset is LYMPHIR, a biologic drug for treating relapsed or refractory cutaneous T-cell ...

George Mulligan, PhD, discusses the ODAC's review of daratumumab for high-risk smoldering multiple myeloma, noting its efficacy in delaying progression but raising questions about patient criteria. In ...

Patricia Chin, a registered nurse, forms meaningful bonds with patients, providing expert care, emotional support and kindness through cancer treatment. My oncology nurse, Patricia Chin, RN, is truly ...